Enanta Pharma (ENTA) Misses Q4 EPS by 27c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. FND
10. GILD

Go back to Enanta Pharma (ENTA) Misses Q4 EPS by 27c

Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017

November 20, 2017 4:01 PM EST

Webcast and Conference Call today at 4:30 p.m. ET

Cash and marketable securities totaled $293.7 million at September 30, 2017 Total revenue for the quarter was $75.9 million Milestone payments totaling $65.0 million received following AbbVies U.S. approval of MAVYRET (glecaprevir/pibrentasvir) and EU approval of MAVIRET (glecaprevir/pibrentasvir) Positive Phase 1 results for EDP-305 support further clinical evaluation in PBC and NASH patients Fast Track designation granted to EDP-305 by the U.S. FDA for the treatment of patients with primary... More